Financial Performance - The total revenue for the year ended December 31, 2019, was RMB 645,885,000, a decrease of 0.3% compared to RMB 647,672,000 in the previous year[16]. - Profit attributable to owners of the Company decreased to RMB 144,726,000 from RMB 161,216,000 in the previous year[16]. - Basic earnings per share decreased to RMB 25.83 cents from RMB 28.78 cents in the previous year[16]. - For the year ended December 31, 2019, the Group's total revenue decreased to RMB 645,885,000 from RMB 647,672,000, representing a decline of 0.3%[34]. - Profit attributable to owners of the Company decreased to RMB 144,726,000 from RMB 161,216,000, marking a reduction of approximately 10.2%[34]. - Basic earnings per share decreased to RMB 25.83 cents from RMB 28.78 cents, reflecting a decline of about 10.3%[34]. - The Group's recorded revenue for the year ended December 31, 2019, was approximately RMB 645,885,000, a decrease of approximately 0.3% compared to RMB 647,672,000 in 2018[47]. - Profit before income tax for 2019 was RMB 175,294,000, down from RMB 186,323,000 in 2018, reflecting a decrease of approximately 5.53%[101]. - Profit attributable to owners of the Company for the year was RMB 144,726,000, compared to RMB 161,216,000 in 2018, indicating a decline of about 10.19%[101]. Investment and R&D - The Company increased investment in technology and intensified product research and development to capture the market with leading technology and high-end products[17]. - The Company emphasized the research and development of new drugs, increasing investment in technologically advanced new drugs with independent intellectual property rights[23]. - The Group invested approximately RMB 41,752,000 in research and development projects during the year[44]. - A new solid medicine workshop was built for research and development of generic drugs, enhancing the Company's product mix and market competitiveness[46]. - The R&D team has filed for three new patents related to drug formulation, which could potentially open new revenue streams[78]. Market Strategy and Challenges - The Company faced challenges such as increasing production costs, dropping drug prices, and rising costs of certain raw materials but achieved its project goals for the year[18]. - The Company aims to pursue sustainable development by exploring and adjusting its business strategy under new historical conditions[17]. - The Company is committed to overcoming market challenges and achieving further success in the coming years[18]. - The Company plans to continue exploring uncharted markets and strengthening academic promotion to maintain its competitive edge[22]. - The Company is expanding its market presence, targeting an increase in distribution channels by 30% in the next year[78]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's R&D capabilities and add $10 million in annual revenue[78]. Financial Management - As of December 31, 2019, the Group's investments in Wealth Management Products amounted to approximately RMB683,483,000, an increase from RMB571,612,000 in 2018[39]. - The gain realized from Wealth Management Products for the year ended December 31, 2019, was approximately RMB11,428,000, down from RMB16,994,000 in 2018, representing a decrease of about 32.5%[39]. - The Group's subscriptions to Wealth Management Products were aimed at maximizing surplus cash utilization while maintaining high liquidity and low risk[39]. - The Group did not experience any losses on the Wealth Management Products as of December 31, 2019, indicating effective treasury management[39]. - The company maintained cash and bank balances of RMB 137,389,000 as of December 31, 2019, down from RMB 158,340,000 in 2018[62]. Corporate Governance - The Company has adopted corporate governance practices, detailed in the annual report[139]. - The Company has complied with the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules throughout the year ended 31 December 2019[141]. - The Audit Committee reviewed the financial reporting procedures and internal control system, including the audited results for the year ended December 31, 2019[137]. - The Company has implemented adequate systems of internal controls and risk management procedures[143]. - The Board meets at least four times a year to discuss business development, operation, and financial performance[145]. Employee Welfare and Social Responsibility - The Group offers competitive remuneration and welfare to employees, enhancing their career development through training[189]. - The Group strictly complies with social insurance regulations, making timely contributions for all staff[191]. - The Group has established a comprehensive management system for occupational health and safety[192]. - The company has actively fulfilled its social responsibilities while balancing development and environmental protection[187]. - A safe and comfortable working environment is prioritized, with reasonable remuneration and various benefits provided to employees[198]. Environmental Impact - The Group advocates green production, achieving energy saving and resource optimization through various measures[187]. - The Group's electricity consumption for the year ended December 31, 2019, was 4,236,000 kWh, coal consumption was 11,556 tonnes, and water consumption was 99,976 tonnes[187]. - The Group has not experienced any significant safety accidents during operations as of December 31, 2019[193].

Financial Performance - The company's revenue for the first quarter of 2020 was RMB 129,952,000, a decrease of 7.2% compared to RMB 140,961,000 in the same period of 2019[4] - Gross profit for the first quarter of 2020 was RMB 111,380,000, down from RMB 118,397,000 in the first quarter of 2019, reflecting a decline of 5.7%[4] - Operating profit for the first quarter of 2020 was RMB 16,964,000, compared to RMB 18,059,000 in the first quarter of 2019, representing a decrease of 6.0%[4] - Profit attributable to shareholders for the first quarter of 2020 was RMB 13,870,000, down 9.1% from RMB 15,261,000 in the same period of 2019[4] - Basic earnings per share for the first quarter of 2020 were 2.47 cents, a decrease from 2.7 cents in the first quarter of 2019[4] - The profit attributable to shareholders for the same period was RMB 13,870,000, down 9% from RMB 15,261,000 in 2019[16] Other Income and Expenses - The company reported other income of RMB 17,182,000, significantly higher than RMB 7,394,000 in the first quarter of 2019, marking an increase of 132.5%[4] - The company’s financial expenses increased to RMB 653,000 in the first quarter of 2020 from RMB 33,000 in the same period of 2019[4] - The effective tax rate for the company remained at 15% for both the first quarter of 2020 and 2019[9] Dividends - The company did not recommend the payment of an interim dividend for the first quarter of 2020, compared to no dividend in the same period of 2019[12] - The total amount of proposed special dividend for the previous financial year is RMB 19,608,750, down from RMB 39,217,500 in 2019[12] Financial Position - The company maintained a strong financial position with cash and bank balances totaling RMB 131,450,000 as of March 31, 2020, down from RMB 150,467,000 in 2019[19] - The net asset value of the group was approximately RMB 1,197,129,000 as of March 31, 2020, compared to RMB 1,148,286,000 in 2019[19] - The company's capital debt ratio was 0.2% as of March 31, 2020, unchanged from the previous year[20] Cost and Production - Distribution and selling costs as a percentage of revenue increased to 78% from 67.4% year-on-year, a rise of 10.6%[16] - The gross margin for the three months ending March 31, 2020, was approximately 85.7%, an increase of 1.7% from 84% in the same period of 2019[16] - The board believes that production and material costs have not experienced significant fluctuations during the reporting period[16] - The company upgraded its production facilities, enhancing capacity to meet market demand, including the construction of a new solid dosage drug workshop[18] - The company is actively developing new products, with the research on Irbesartan tablets completed[18] Corporate Governance - The audit committee was established on May 24, 2001, to review and supervise the financial reporting procedures and internal control systems of the group[43] - The board believes that having an executive chairman is in the best interest of the group, as it facilitates open communication between the board and management[42] Share Activity - The company has not purchased, sold, or redeemed any of its listed shares during the three months ending March 31, 2020[45]

吉林省輝南長龍生化藥業股份有限公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 第三季度業績報告2019 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在本交易所上市的公司帶有較高投資風險的公司提供一 個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。GEM的較高風險及其它特色表示GEM較適合專業及其他 老練投資者。 由於GEM上市公司新興的性質所然，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不會就因本報告全部或部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（吉林省輝南長龍生化藥業股份有限公司的董事（「董事」）願共同及個別對此負全 責）乃 遵 照GEM證 券 上 ...

Financial Performance - Revenue for the six months ended June 30, 2019, was RMB 299,404,000, a decrease of 4.3% compared to RMB 312,070,000 for the same period in 2018[5] - Gross profit for the same period was RMB 248,926,000, down 2.9% from RMB 256,522,000 in 2018[5] - Operating profit for the six months was RMB 62,985,000, a decrease of 3.9% compared to RMB 65,490,000 in 2018[5] - Profit attributable to shareholders for the six months was RMB 53,473,000, down 3.8% from RMB 55,522,000 in 2018[5] - Basic earnings per share for the six months was 9.54 cents, compared to 9.91 cents in 2018[5] - For the six months ended June 30, 2019, the total revenue was RMB 320,411,000, a decrease of 2.3% compared to RMB 328,453,000 for the same period in 2018[18] - The net profit for the six months ended June 30, 2019, was RMB 53,472,000, compared to RMB 55,522,000 for the same period in 2018, reflecting a decrease of 3.8%[23] - The basic earnings per share for the six months ended June 30, 2019, was RMB 0.095, compared to RMB 0.099 for the same period in 2018[23] Cash Flow and Assets - Cash inflow from operating activities was RMB 47,214,000, a significant improvement from a cash outflow of RMB 40,675,000 in 2018[8] - Total assets as of June 30, 2019, were RMB 1,575,295,000, compared to RMB 1,554,861,000 as of December 31, 2018[7] - Total liabilities as of June 30, 2019, were RMB 388,798,000, compared to RMB 421,836,000 as of December 31, 2018[7] - Net cash and cash equivalents at the end of the period were RMB 148,617,000, down from RMB 159,026,000 at the beginning of the period[8] - As of June 30, 2019, the company had cash and bank balances of approximately RMB 148,617,000, with a total net asset value of approximately RMB 1,186,497,000[47] - The company’s non-current assets at the end of June 30, 2019, were RMB 15,068,000, unchanged from the previous year[31] - The company’s trade receivables as of June 30, 2019, totaled RMB 276,343,000, compared to RMB 249,326,000 as of December 31, 2018[39] Expenses and Taxation - The operating profit for the six months ended June 30, 2019, included depreciation of RMB 10,638,000, down from RMB 16,716,000 in the same period of 2018[20] - The income tax expense for the six months ended June 30, 2019, was RMB 9,449,000, slightly lower than RMB 9,875,000 for the same period in 2018[20] - Selling expenses accounted for 61% of revenue for the six months ended June 30, 2019, a decrease from 62.3% in the same period of 2018[44] - General and administrative expenses increased from RMB 12,809,000 for the six months ended June 30, 2018, to RMB 24,798,000 for the same period in 2019[44] - The applicable income tax rate remained at 15% for both 2019 and 2018[20] Dividends and Shareholder Information - The company did not declare any dividends for the current period, consistent with the previous year[5] - The company did not recommend any interim dividend for the six months ended June 30, 2019, consistent with the previous year[24] - The major shareholder, Mr. Zhang Hong, holds 101,937,000 shares, representing 26.29% of domestic shares and 18.19% of total registered capital[54] - The company has not repurchased, sold, or redeemed any of its listed shares during the six-month period ending June 30, 2019[67] Corporate Governance and Future Outlook - The company has established an audit committee composed of three independent non-executive directors to oversee financial procedures and internal controls[63] - The company will continue to explore potential business opportunities to drive growth and achieve better results in the future[52] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[61] - The board of directors includes 6 executive directors and 3 independent non-executive directors[68] - The mid-year performance report will be published on the GEM website for seven consecutive days starting from the publication date[69] - The report is dated August 14, 2019, indicating a mid-year performance review[70] Business Operations - The company operates solely in the production and distribution of traditional Chinese medicine and pharmaceutical products within China[20] - The company has invested in research and development in the food and health sectors to enhance its pharmaceutical research capabilities[45] - The company completed the construction and commissioning of equipment for its wholly-owned subsidiary, Jilin Changlong Food and Beverage Co., Ltd., and launched the product "Changbai Mountain Wild Walnut Milk"[45] - The company employed 870 employees as of June 30, 2019, an increase from 520 employees on June 30, 2018[66] - The company has not recognized any significant deferred tax assets for the periods ended June 30, 2019, and 2018[21]

吉林省輝南長龍生化藥業股份有限公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 第一季度業績報告2019 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位，乃為相比起其他在本交易所上市的公司帶有較高投資風險的公司提供一 個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專業及其他 老練投資者。 由於GEM上市公司新興的性質使然，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不會就本報告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 本報告乃遵照GEM證券上市規則提供有關吉林省輝南長龍生化藥業股份有限公司及其 附 屬 公 司（「本 集 團」）之 資 料，吉 ...

Financial Performance - The total revenue for the year ended December 31, 2018, was RMB 647,672,000, representing an increase of 0.4% compared to RMB 645,303,000 in the previous year[19]. - Profit attributable to owners of the Company increased to RMB 161,216,000 from RMB 144,402,000 last year[19]. - Basic earnings per share rose to RMB 28.78 cents from RMB 25.77 cents in the previous year[19]. - The profit attributable to equity holders increased from RMB 144,402,000 to RMB 161,216,000, reflecting a growth of approximately 11.8%[22]. - Basic earnings per share rose from RMB 25.77 to RMB 28.78, marking an increase of about 7.8%[22]. - For the year ended 31 December 2018, the Group's revenue increased to approximately RMB 647,672,000, representing a growth of about 0.4% compared to RMB 645,303,000 in 2017[30]. - The profit attributable to owners of the Company for the year was approximately RMB 161,216,000, an increase of 11.6% from RMB 144,402,000 in the previous year[31]. - Basic earnings per share rose to RMB 28.78 cents, up from RMB 25.77 cents, reflecting an increase of RMB 3.01 cents[31]. - The gross profit margin for the year ended December 31, 2018, was approximately 82.2%, a decrease of 0.1% from 82.3% in 2017[33]. - Other income and gains for the year ended December 31, 2018, were approximately RMB 58,188,000, compared to RMB 24,008,000 in 2017[33]. - Distribution and selling costs increased to approximately RMB 375,480,000 in 2018, accounting for 57.97% of revenue, up from 51.93% in the previous year, representing a 6.04% increase[33]. - Administrative expenses decreased to approximately RMB 28,450,000 in 2018 from RMB 47,165,000 in 2017[33]. - The financial performance for 2018 indicates a stable growth trajectory, with detailed figures available in the annual report[57]. Product Development and Innovation - The company focused on the sales growth of its leading product, Hai Kun Shen Xi capsule, and expanded sales of its branded product, Compound Huonaoshu capsule[21]. - The company emphasized research and development of new drugs, collaborating with pharmaceutical universities and research institutes to enhance technological advancements[26]. - The R&D department successfully developed the Hai Kun Shen Xi capsule, which has become the largest contributor to revenue[31]. - The Group launched a new product, Changbai Mountain wild walnuts milk, through its wholly-owned subsidiary, enhancing its product offerings[31]. - The company has been involved in the research and development of new medicines, including Infantile spleen-strengthening oral solution and Ginseng Glycopeptide Injection[52]. - The company has achieved a leading international level in research studies related to ginseng polysaccharide[52]. - The company is committed to expanding its market presence and enhancing its product offerings through ongoing research and development efforts[52]. - Jilin Province Huinan Changlong Bio-pharmacy Company Limited reported significant advancements in drug development, with three new drugs successfully developed, including pediatric health tonic and ginseng peptide injection[54]. - The company has revised and improved nearly 100 drug standards, which have been successfully transformed in local enterprises[54]. - The company holds five invention patents, showcasing its commitment to innovation in the pharmaceutical sector[54]. - The company has a strong focus on innovation, as evidenced by the patents and awards received by its team members[44][52]. Corporate Governance and Management - The Board of Directors expressed satisfaction with the financial performance, attributing profitability to strong sales and distribution efforts[31]. - The Audit Committee was established on May 24, 2001, to oversee financial reporting and internal control systems[104]. - The Company has complied with the Corporate Governance Code as set out in Appendix 15 of the GEM Listing Rules throughout the year ended December 31, 2018[109]. - The Board comprises nine Directors, with six Executive Directors and three Independent Non-Executive Directors (INEDs) as of the report date[112]. - The Audit Committee is composed exclusively of Independent Non-Executive Directors, ensuring independent oversight[121]. - The Company has implemented adequate systems of internal controls and risk management procedures as part of its corporate governance practices[112]. - The Company has provided continuous professional development for Directors to keep them updated on statutory and regulatory changes[129]. - The Remuneration Committee is responsible for determining specific remuneration packages for all Executive Directors, considering factors like comparable salaries and performance-based remuneration[136]. - The Nomination Committee evaluates potential candidates based on professional expertise, relevant experience, and personal integrity[147]. - The Company ensures that all Directors receive tailored induction and ongoing updates to facilitate their responsibilities under GEM Listing Rules[128]. Environmental and Social Responsibility - The Company is committed to energy saving, consumption reduction, and minimizing environmental impact through various initiatives[180]. - The Group has complied with the "comply or explain" provisions of the Environmental, Social and Governance Reporting Guide[179]. - The Company has established a comprehensive management system for occupational health and safety, with no significant safety incidents reported as of December 31, 2018[187]. - The Group actively fulfills its social responsibilities while balancing development and environmental protection[180]. - The Company has implemented a recycling system to reduce water resource usage during production[181]. - The Group emphasizes the importance of product compliance and conducts self-inspections to manage quality and safety risks[193]. - The Group actively engages with local communities to contribute to their development and encourages staff to volunteer their time and skills[196]. Financial Position and Assets - As of December 31, 2018, the Group's total assets were RMB 1,554,841,000, an increase from RMB 1,238,072,000 in 2017[33]. - The ratio of total liabilities to total assets was 27% in 2018, up from 18% in 2017, with total liabilities amounting to RMB 421,816,000[36]. - The Group had a gearing ratio of 0.2% as of December 31, 2018, compared to 0.3% in 2017[36]. - The Group maintained cash and bank balances of RMB 158,340,000 as of December 31, 2018, compared to RMB 110,428,000 in 2017[36]. - Total assets as of December 31, 2018, amounted to RMB 1,554,841,000, a significant increase from RMB 1,238,072,000 in 2017, representing a growth of about 25.5%[63]. - Total liabilities increased to RMB 421,816,000 in 2018 from RMB 227,045,000 in 2017, marking an increase of approximately 85.7%[63]. - Net assets rose to RMB 1,133,025,000 in 2018, compared to RMB 1,011,027,000 in 2017, indicating a growth of about 12.0%[63]. Compliance and Risk Management - The Group's operations comply with local and national anti-corruption legislation, including the Prevention of Bribery Ordinance in Hong Kong[196]. - Employees are required to adhere to a code of business ethics, prohibiting any corrupt or bribery behavior as per employment contracts[196]. - The Group is committed to identifying, monitoring, and managing risks associated with its business activities through an effective control system[160]. - The internal control system of the Group is reviewed continuously by the Board, which is satisfied that the current internal controls are satisfactory[160].